DCF Advisers LLC Takes $2.09 Million Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Posted by Brenda Bartman on Jun 11th, 2026

DCF Advisers LLC acquired a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) during the fourth quarter, Holdings Channel.com reports. The firm acquired 30,000 shares of the company’s stock, valued at approximately $2,086,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. State of Wyoming acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $28,000. EverSource Wealth Advisors LLC boosted its holdings in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares in the last quarter. CWM LLC boosted its holdings in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares in the last quarter. ANTIPODES PARTNERS Ltd boosted its holdings in Structure Therapeutics by 39.1% in the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after purchasing an additional 1,146 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Structure Therapeutics during the second quarter worth about $129,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR opened at $41.53 on Thursday. The stock has a fifty day moving average price of $43.89 and a 200 day moving average price of $57.21. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $15.80 and a 1-year high of $94.90. The company has a market cap of $2.95 billion, a PE ratio of -47.74 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. Analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. HC Wainwright decreased their price objective on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 16th. Finally, Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $109.25.

View Our Latest Stock Analysis on GPCR

Structure Therapeutics Profile

(Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.